Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial
Top Cited Papers
Open Access
- 27 August 2015
- journal article
- research article
- Published by Elsevier BV in Journal of Clinical Lipidology
- Vol. 9 (6), 758-769
- https://doi.org/10.1016/j.jacl.2015.08.006
Abstract
No abstract availableKeywords
Funding Information
- Regeneron Pharmaceuticals
This publication has 27 references indexed in Scilit:
- Treatment strategies in patients with statin intolerance: The Cleveland Clinic experienceAmerican Heart Journal, 2013
- Effect of Statins on Skeletal Muscle FunctionCirculation, 2013
- Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin TherapyJournal of the American College of Cardiology, 2012
- Diagnosis, Prevention, and Management of Statin Adverse Effects and Intolerance: Proceedings of a Canadian Working Group Consensus ConferenceCanadian Journal of Cardiology, 2011
- ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)European Heart Journal, 2011
- Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trialsThe Lancet, 2010
- Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta‐analysis of randomized controlled trialsJournal of Internal Medicine, 2009
- MMRM vs. LOCF: A Comprehensive Comparison Based on Simulation Study and 25 NDA DatasetsJournal of Biopharmaceutical Statistics, 2009
- Long-term persistence with statin treatment in a not-for-profit health maintenance organization: A population-based retrospective cohort study in IsraelClinical Therapeutics, 2008
- Reduction of LDL Cholesterol by 25% to 60% in Patients With Primary Hypercholesterolemia by Atorvastatin, a New HMG-CoA Reductase InhibitorArteriosclerosis, Thrombosis, and Vascular Biology, 1995